Martin Lange - Novo Nordisk Head VP
| 0QIU Stock | 742.30 14.79 2.03% |
VP
Martin Lange is Head VP of Novo Nordisk AS
| Age | 54 |
| Address | Novo Allé 1, Bagsvaerd, Denmark, 2880 |
| Phone | 45 44 44 88 88 |
| Web | https://www.novonordisk.com |
Novo Nordisk Management Efficiency
The company has return on total asset (ROA) of 0.2176 % which means that it generated a profit of $0.2176 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.8154 %, meaning that it generated $0.8154 on every $100 dollars invested by stockholders. Novo Nordisk's management efficiency ratios could be used to measure how well Novo Nordisk manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Novo Nordisk's Intangible Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 33.7 B in 2024, whereas Total Assets are likely to drop slightly above 149.2 B in 2024.Similar Executives
| Found 3 records | VP Age | ||
| Robert Axel | Prudential Financial | N/A | |
| Stacey Goodman | Prudential Financial | 61 | |
| Jeffrey Kutz | Air Products Chemicals | 64 | |
Management Performance
| Return On Equity | 0.82 | ||||
| Return On Asset | 0.22 |
Novo Nordisk AS Leadership Team
Elected by the shareholders, the Novo Nordisk's board of directors comprises two types of representatives: Novo Nordisk inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novo. The board's role is to monitor Novo Nordisk's management team and ensure that shareholders' interests are well served. Novo Nordisk's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novo Nordisk's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Monique Carter, Head VP | ||
| Maziar Doustdar, Head VP | ||
| Lars Jorgensen, CEO Pres | ||
| Marcus Schindler, Head EVP | ||
| Karsten Knudsen, CFO VP | ||
| Henrik Wulff, Head VP | ||
| Ludovic Helfgott, Head VP | ||
| Camilla Sylvest, Head VP | ||
| Martin Lange, Head VP | ||
| Douglas Langa, Head VP |
Novo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novo Nordisk a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.82 | ||||
| Return On Asset | 0.22 | ||||
| Profit Margin | 0.33 % | ||||
| Operating Margin | 0.43 % | ||||
| Current Valuation | 2.96 T | ||||
| Shares Outstanding | 2.41 B | ||||
| Shares Owned By Insiders | 5.98 % | ||||
| Shares Owned By Institutions | 41.95 % | ||||
| Price To Sales | 0.12 X | ||||
| Revenue | 140.8 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Novo Stock Analysis
When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.